Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Clymer

Podiatrist, Foot & Ankle Surgery Castle Pines, CO Doctor of Podiatric Medicine

NPI 1447511035 CMS profile 1391108

7505 Village Square Dr Ste 101, Castle Pines, CO 80108

Open in the dashboard

General payments

$5,785

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Clymer of Castle Pines, CO is reported in the CMS Open Payments database as having received $5,785 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,068 14
2024 General $440 8
2023 General $1,341 12
2022 General $29 1
2021 General $1,216 2
2020 General $625 1
2019 General $1,066 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Clymer
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Daniel Clymer were reported at $1,068. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Daniel Clymer Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,066 $389 $118–$1,406 $163
2020 $625 $191 $62–$691 $114
2021 $1,216 $329 $104–$1,341 $132
2022 $29 $419 $125–$1,611 $149
2023 $1,341 $377 $128–$1,164 $160
2024 $440 $394 $134–$1,168 $164
2025 $1,068 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gemini Mountain Medical, LLC $3,244 8 payments
  2. Arthrex, Inc. $589 8 payments
  3. Organogenesis Inc. $442 6 payments
  4. Smith+Nephew, Inc. $415 3 payments
  5. Voom Medical Devices, Inc. $370 3 payments
  6. Treace Medical Concepts, Inc. $304 5 payments
  7. NuVasive, Inc. $229 1 payment
  8. Medtronic, Inc. $112 3 payments
  9. Bioventus LLC $45 2 payments
  10. Djo, LLC $34 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,662 3 payments
  2. Food and Beverage $2,022 34 payments
  3. Travel and Lodging $1,100 3 payments
Products named General payments · program years 2019–2025
  1. REVCON $321 2 payments
  2. Puraply $273 3 payments
  3. Osteocel $229 1 payment
  4. TMC NANOPLASTY SYSTEM $175 3 payments
  5. Affinity $149 2 payments
  6. NOVACHOR $149 2 payments
  7. GRAFIX PL Other Advanced Wound Management $145 1 payment
  8. GRAFIX $136 1 payment
  9. GRAFIX PL Other Advanced Wound Management $134 1 payment
  10. INTELLIS ADAPTIVESTIM $112 3 payments
  11. Other $145 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

62

Median for Podiatry: 160

Drug cost

$1,436

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 27 $729
Clotrimazole Generic 20 $547
Cefadroxil Generic 15 $161

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$91,333

Of which drugs: $22,133

Medicare patients

242

Average age 74

Services billed

1,446

133 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 60%
Ischemic heart disease 26%
Osteoporosis 26%
Chronic kidney disease 25%
Diabetes 24%
Depression 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 20 $14
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 54 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record